CDE Grants Priority Review to Pearl Biotech’s Breatinib for Glioblastoma Treatment
China’s Center for Drug Evaluation (CDE) has indicated that Beijing Pearl Biotechnology Co., Ltd’s breatinib...
Drug
BMS’s Subcutaneous Opdivo Meets Phase III Study Endpoints in ccRCC
Bristol-Myers Squibb (BMS; NYSE: BMY) has announced positive results from a Phase III comparative study...
AstraZeneca’s Soliris Gains Approval in China for NMOSD Treatment
UK-based pharmaceutical giant AstraZeneca Plc (AZ, NASDAQ: AZN) has announced that its rare disease drug...
Qilu Pharmaceutical Presents Promising Data for QL1706 and QL1209 at ESMO 2023
China-based Qilu Pharmaceutical has announced the presentation of clinical data for two of its pipeline...
Guangdong Zhongsheng Launches AI Q&A Bot for Leritrelvir Drug Support
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the innovative launch of a...
Boehringer Ingelheim’s Vitiligo Drug EI-001 Approved for Clinical Trials by NMPA
Germany’s Boehringer Ingelheim (BI) has announced that the National Medical Products Administration (NMPA) has approved...
Haisco Pharmaceutical’s HSK21542 Accepted for NMPA Review in Postoperative Pain Management
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its clinical trial filing...
Roche’s Alecensa Shows Unprecedented 76% Improvement in Disease-Free Survival in NSCLC Trial
Roche (SWX: ROG) subsidiary Genentech has revealed preliminary but promising results from a Phase III...
MicuRx Pharmaceuticals Initiates Phase I Study for MRX-5 in Australia
Sino-US firm MicuRx Pharmaceuticals Inc. has announced the approval to conduct a Phase I clinical...
GenScript Reports $152 Million in Sales for Carvykti as of September 30, 2023
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary,...
Novartis Launches Leqvio in China at RMB 9,988 per Shot
Swiss pharmaceutical giant Novartis (NYSE: NVS) has officially launched its cholesterol-lowering drug, Leqvio (inclisiran), in...
Zhejiang Huahai Pharmaceutical Secures Orphan Drug Designation for HB0034
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that it has received orphan...
BeiGene’s Tislelizumab Shows Promising Results in ESMO Presentations for GC/GEJC and NSCLC
China-based biotech BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced two late-breaking presentations...
BeiGene Submits Supplementary BLA for Tislelizumab in Small Cell Lung Cancer
BeiGene (NASDAQ: BGNE) has announced that its supplementary Biologic License Application (sBLA) for the programmed...
Mabwell to Present Promising Clinical Data at 2023 ESMO Congress
China-based Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has announced that it will present the...
Asieris Pharma Launches Generic Votrient for Renal Cell Carcinoma in China
China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd, trading as Asieris Pharma (SHA: 688176),...
BeiGene’s Brukinsa Receives Positive CHMP Opinion for Follicular Lymphoma Treatment
China-based biotechnology leader BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced the receipt of...
Eli Lilly’s Tirzepatide Shows Robust Weight Loss Results in Phase III Study
Eli Lilly (NYSE: LLY) has released compelling efficacy results from a Phase III study evaluating...
Simcere’s SIM0237 Receives NMPA Approval for Bladder Cancer Trial
China-based pharmaceutical innovator Simcere Pharmaceutical Group (HKG: 2096) has announced the receipt of an additional...
Abbisko Therapeutics to Unveil Phase I Data for ABSK011 and ABSK043 at ESMO 2023
Shanghai-based biotech powerhouse Abbisko Therapeutics Co., Ltd (HKG: 2256) is preparing to present the results...